Shanghai RAAS Blood Products: Net profit dropped 26% on flat revenue, with major buybacks and clinical trial advances

Net asset value reached ¥189.41 million with A/B shares up 4.64% and C shares up 4.38% versus a 0.12% benchmark. Equity exposure dominated, and the outlook remains optimistic for H2 2025, focusing on gold, metals, and new consumption.

Original document: Shanghai RAAS Blood Products Co., Ltd. Class A [002252] Interim report — Aug. 30 2025

China's drug administration approved Shanghai RAAS Blood Products' phase 2B clinical trial for its anti-hemophilia A/B or blood-clotting disorder injection, according to a Wednesday filing with the Shenzhen bourse.

The trial will evaluate the safety, tolerability, immunogenicity, or ability to trigger an immune response, and pharmacokinetic characteristics or absorption, distribution, metabolism, and excretion of SR604, the filing said.

Shanghai RAAS Blood Products finalized its 4.2-billion-yuan acquisition of Nanyue Biopharmaceutical, following regulatory approvals and industrial registration updates.

The deal includes a 50-million-yuan contingent payment if Nanyue Biopharmaceutical achieves 305 tons of plasma collection in 2025, according to a Friday filing with the Shenzhen bourse.

Shanghai RAAS Blood Products completed the appointment of directors, supervisors and senior management for Nanyue Biopharmaceutical, now a wholly-owned subsidiary.

Q1 2025 saw revenue and net profit decline year-over-year, but operating cash flow improved. Major developments include a share buyback, controlling shareholder stake increase, and the acquisition of Nanyue Biopharmaceutical to expand plasma resources.

Original document: Shanghai RAAS Blood Products Co., Ltd. Class A [002252] Interim report — Apr. 28 2025

Shanghai RAAS Blood Products net profit attributable to shareholders in 2024 climbed 23% to 2.19 billion yuan from 1.78 billion yuan a year earlier, according to a Shenzhen Stock Exchange filing on Friday.

Earnings per share rose 22% year on year to 0.33 yuan from 0.27 yuan.

The Chinese blood products maker's operating income grew 2.7% to 8.18 billion yuan from 7.96 billion yuan in the previous year, the filing said.

The company's shares jumped less than 5% in recent trade.

Shanghai RAAS achieved 2.67% revenue growth and 23.25% net profit growth in 2024, completed a major change in control to Haier Group, and announced a significant acquisition to expand plasma resources, while maintaining strong margins and investing in R&D.

Original document: Shanghai RAAS Blood Products Co., Ltd. Class A [002252] Annual Report — Apr. 17 2025